Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer

(2020) Lei Zhang et al.   CELL

MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).

(2019) Philippe Alexandre Cassier et al.   JOURNAL OF CLINICAL ONCOLOGY

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

(2019) William D Tap et al.   LANCET

Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?

(2019) François Ghiringhelli et al.   Frontiers in Immunology

Mechanisms of resistance to immune checkpoint inhibitors

(2018) Russell W Jenkins et al.   BRITISH JOURNAL OF CANCER

De-novo and acquired resistance to immune checkpoint targeting

(2017) Nicholas L Syn et al.   LANCET ONCOLOGY

Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies

(2017) Mattia Bonsignori et al.   Science Translational Medicine

Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies

(2016) Daniela F. Quail et al.   CLINICAL CANCER RESEARCH

CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

(2015) Philippe A Cassier et al.   LANCET ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased Serum Enzyme Levels Associated with Kupffer Cell Reduction with No Signs of Hepatic or Skeletal Muscle Injury

(2011) Zaher A. Radi et al.   AMERICAN JOURNAL OF PATHOLOGY